Health
Takeda To Develop Zika Vaccine With $312m

By Modupe Gbadeyanka
Japanese firm, Takeda Pharmaceutical Company Limited, has announced that the Biomedical Advanced Research and Development Authority (BARDA) has selected its Vaccine Business Unit to develop a vaccine to support the Zika response in the US and affected regions around the world.
Initial funding from BARDA, which is a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services, is for $19.8 million to cover the vaccine development through Phase 1, with potential funding of up to $312 million if ASPR/BARDA exercises all options to take the vaccine through Phase 3 trials and filing of the Biologics License Application (BLA) in the US.
On February 1, 2016, the World Health Organization declared the Zika outbreak to be a Public Health Emergency of International Concern. On February 8, 2016 the Centers for Disease Control and Prevention (CDC) elevated its Zika response efforts to its highest response level, Level 1. There is no vaccine or medicine for Zika2, and infection during pregnancy can cause a serious birth defect called microcephaly and other severe fetal brain defects.
Current research suggests that Guillain-Barre syndrome (GBS), which is an uncommon sickness of the nervous system, is strongly associated with Zika; however, only a small proportion of people with recent Zika virus infection get GBS. Many people infected with Zika will have no symptoms or mild symptoms that last several days to a week. The virus has spread in recent years into more than 60 countries and territories including the US.
Dr Rajeev Venkayya, Corporate Officer and President of the Global Vaccine Business Unit at Takeda, said: “The Zika emergency demands swift action by governments, public health agencies, medical and scientific communities, industry and others, and partnerships are essential for success.
“Working with BARDA, Takeda is deploying its world-class expertise and capabilities in vaccine development for emerging infectious diseases, and our outstanding team and manufacturing facilities in Hikari, Japan.
“This Zika vaccine program joins our work in dengue, norovirus, our partnership with the Japanese Government on pandemic influenza, and the recently announced partnership with the Bill & Melinda Gates Foundation to help eradicate polio.
“These efforts to develop a vaccine against the Zika virus reinforce Takeda’s commitment to the health of people everywhere, including the most vulnerable populations that are threatened by Zika.”
Given the Japanese Government’s commitment to preparedness for outbreaks of infectious diseases, recently reinforced by Prime Minister Abe at the G7 Summit in Ise-Shima, Japan, Takeda is in discussions with the Cabinet Secretariat of the Prime Minister Office regarding potential participation of Japanese health agencies in this collaboration. Takeda is working with ASPR/BARDA and the Japanese Government to explore these opportunities further.
Under the agreement, Takeda will develop an inactivated, adjuvanted, whole Zika virus vaccine. The objectives of the first stage of the work include developing and producing the investigational vaccine and completing pre-clinical studies, submission of an Investigational New Drug Application (IND) to the US Food and Drug Administration, and execution of a Phase 1 clinical trial. Manufacturing of the vaccine will occur at Takeda’s facilities in Hikari, Japan.
Takeda’s Commitment to Vaccines
Vaccines prevent more than two million deaths each year and have transformed global public health. For 70 years, Takeda has supplied vaccines to protect the health of people in Japan.
Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, norovirus and polio. Our team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs.
Health
Adichie Demands Documentation of Late Son’s Treatment as Euracare Suspends Doctor
By Adedapo Adesanya
Nigerian author, Ms Chimamanda Ngozi Adichie, via her solicitors, has written to Euracare Multi-Specialist Hospital, Lagos, over the death of her 21-month-old son, Nkanu Nnamdi, seeking documentation of treatment before his untimely demise.
In a legal notice dated January 10, 2026, solicitors acting for the renowned author and her partner, Dr Ivara Esege, alleged that the hospital, its anaesthesiologist, and attending medical personnel breached the duty of care owed to their son, who died in the early hours of Wednesday, January 7, 2026.
The notice was issued on behalf of the parents by Pinheiro LP and signed by the founding partner, Prof Kemi Pinheiro (SAN).
According to the notice, the child was referred to the hospital on January 6, 2026, from Atlantis Pediatric Hospital for a series of diagnostic and preparatory procedures. These included an echocardiogram, a brain MRI, the insertion of a peripherally inserted central catheter (PICC line), and a lumbar puncture.
The procedures were reportedly part of preparations for an imminent medical evacuation to the United States, where a specialist medical team was said to be on standby to receive him.
The solicitors stated that intravenous sedation was administered using propofol.
However, it was alleged that during transportation to the cardiac catheterisation laboratory following the MRI procedure, the child allegedly developed sudden and severe complications.
Despite being under sedation, he was said to have been transferred between clinical areas under conditions that raised “serious and substantive concerns” about compliance with patient-safety protocols.
He was later pronounced dead in the early hours of January 7, 2026.
The legal notice outlines multiple alleged lapses in paediatric anaesthetic and procedural care.
These include concerns about the appropriateness and cumulative dosing of propofol in a critically ill child, inadequate airway protection during deep sedation, and an alleged failure to ensure continuous physiological monitoring.
The parents further alleged that their son was transferred without supplemental oxygen, without adequate monitoring, and without sufficient accompanying medical personnel.
They also raised concerns over the availability of basic resuscitation equipment, delayed recognition and management of respiratory or cardiovascular compromise, and an overall failure to comply with established paediatric anaesthesia, patient-transfer, and safety protocols.
Another major grievance cited was the alleged failure of the hospital to adequately disclose the risks and potential side effects of propofol and other anaesthetic agents, thereby undermining the legal requirement for informed consent.
According to the solicitors, these alleged lapses amount to prima facie breaches of the duty of care and render the hospital and all medical personnel involved liable for medical negligence resulting in the child’s death.
As part of their next legal steps, the parents demanded certified copies of all medical records relating to their son’s treatment within seven days of receipt of the notice.
The requested documents include admission notes, consent forms, pre-anaesthetic assessments, anaesthetic charts, drug administration records, monitoring logs, procedural notes, nursing observations, ICU records, incident reports, and the identities of all medical staff involved.
The demand also covers internal reviews, safety logs from the MRI suite, and any other documentation connected to the child’s care.
The hospital was also formally placed on notice to preserve all relevant evidence, whether physical or electronic.
This includes CCTV footage from procedure rooms and corridors, electronic monitoring data, pharmacy and drug inventory records, crash-cart and emergency equipment logs, as well as internal communications and any morbidity and mortality reviews.
The solicitors warned that “any destruction, alteration, or loss of such evidence after receipt of this letter shall be regarded as suppression or concealment of evidence and obstruction of the course of justice, and will be relied upon accordingly, with attendant legal consequences.”
The letter concluded with a warning that failure or refusal by the hospital to comply with the demands within the stipulated timeframe would leave the parents with no option but to pursue all available legal, regulatory, and judicial remedies against the hospital and all medical personnel involved.
Euracare Hospital had noted in a Saturday statement that it had commenced “a detailed investigation” into the incident in line with its clinical governance standards and best practices, while pledging to engage transparently and responsibly with all relevant clinical and regulatory processes.
Also, the Lagos State Government on Saturday said it began an investigation into the incident, vowing to ensure the full weight of the law is applied.
Speaking yesterday, the Special Adviser to the Lagos State Governor on Health, Dr Kemi Ogunyemi, said the doctor involved in the child’s procedure had been suspended by the hospital’s management, noting that the hospital was cooperating with the government in the investigation.
“The hospital itself is also doing its own internal investigation, and as far as we know, the anaesthesiologist involved has been suspended by the hospital,” she revealed.
Health
Chinamanda Ngozi Adichie Blames Medical Negligence for Son’s Death
By Adedapo Adesanya
Renowned Nigerian author, Ms Chinamanda Ngozi Adichie, has alleged that medical negligence was responsible for the death of her 21-month-old child.
The child, Nkanu, reportedly passed away on Wednesday, January 7, 2026, after a brief illness.
More details have emerged detailing the circumstances surrounding his death.
According to a leaked internal message sent privately to family members and close friends, Ms Adichie blamed a staff of Euracare Multi-Specialist Hospital, located in Victoria Island, Lagos, for causing the demise of the lad.
“My son would be alive today if not for an incident at Euracare Hospital on January 6th.
“We were in Lagos for Christmas. Nkanu had what we first thought was just a cold, but soon turned into a very serious infection and he was admitted to Atlantis hospital.
“He was to travel to the US the next day, January 7th, accompanied by Travelling Doctors. A team at Johns Hopkins was waiting to receive him in Baltimore. The Hopkins team had asked for a lumbar puncture test and an MRI. The Nigerian team had also decided to put in a ‘central line’ (used to administer iv medications) in preparation for Nkanu’s flight. Atlantis hospital referred us to Euracare Hospital, which was said to be the best place to have the procedures done.
“The morning of the 6th, we left Atlantis hospital for Euracare, Nkanu carried in his father’s arms. We were told he would need to be sedated to prevent him from moving during the MRI and the ‘central line’ procedure.
“I was waiting just outside the theater. I saw people, including Dr M, rushing into the theater and immediately knew something had happened.
“A short time later, Dr M came out and told me Nkanu had been given too much propofol by the anesthesiologist, had become unresponsive and was quickly resuscitated. But suddenly Nkanu was on a ventilator, he was intubated and placed in the ICU. The next thing I heard was that he had seizures. Cardiac arrest. All these had never happened before. Some hours later, Nkanu was gone
“It turns out that Nkanu was NEVER monitored after being given too much propofol. The anesthesiologist had just casually carried Nkanu on his shoulder to the theater, so nobody knows when exactly Nkanu became unresponsive.
“How can you sedate a sick child and neglect to monitor him? Later, after the ‘central line’ procedure, the anesthesiologist casually switched off Nkanu’s oxygen and again decided to carry him on his shoulder to the ICU!
“The anesthesiologist was CRIMINALLY negligent. He was fatally casual and careless with the precious life of a child. No proper protocol was followed.
“We brought in a child who was unwell but stable and scheduled to travel the next day. We came to conduct basic procedures. And suddenly, our beautiful little boy was gone forever. It is like living your worst nightmare. I will never survive the loss of my child.
“We have now heard about two previous cases of this same anesthesiologist overdosing children. Why did Euracare allow him to keep working? This must never happen to another child,” she wrote.
As of press time, it is not clear what the next line of action will be with the revelation.
Health
SUNU Health Named Most Customer Focused HMO of the Year
By Modupe Gbadeyanka
The decision of the management of SUNU Health Nigeria Limited to adopt the strategy of placing the enrollee and customer at the heart of its operations has started to pay off.
The company was recently announced as Most Customer-Focused Health Insurance Company of the Year at the Customer Service Standard Magazine Awards 2025.
The recognition underscored the company’s success in translating its dedication into tangible enrollee satisfaction and superior market service at the Nigerian Health Maintenance Organisation (HMO) landscape.
It also highlights the organisation’s dedicated efforts in streamlining claims processing, enhancing access to quality healthcare providers, and maintaining transparent, responsive communication channels with its diverse client base across Nigeria.
The accolade further serves as a powerful testament to the successful integration of digital solutions and human-centric service models at SUNU Health.
It positions the firm as a leader not only in providing robust health plans but also in delivering the supportive, personalized care that enrollees truly value.
“Clinching the Most Customer-Focused Health Insurance Company of the Year award is not just an honour; it is a validation of the core philosophy that drives every member of the SUNU Health team.
“We believe that healthcare is fundamentally a service industry, and our success is measured by the well-being and satisfaction of our enrollees,” the chief executive of SUNU Health, Mr Patrick Korie, commented.
“This award reinforces our resolve to continuously innovate and set new benchmarks for customer experience in the Nigerian health insurance sector.
“Our commitment to providing accessible, high-quality, and seamless healthcare solutions remains our top priority as we move into the new year (2026),” he added.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn












